Launch of Next-Generation Clinical Trial Data Platform
Rutland, MA, Oct. 5, 2017- A brand new clinical trial database and collaborative platform was launched on October 3, with the aim of being the leading source for every clinical trial data need. PrimaryEndpoints.com will serve a broad audience of biotech investors, clinical researchers, patients, and their advocates.
The revolutionary website offers several features previously unavailable, including:
· Crowdsourced trial predictions.
· Data visualizations of clinical trial data.
· Trial events and results.
· Personalized watchlists.
· Access to biotech gurus.
· Trial-centric discussions.
The site’s sleek modern design showcases all of the data available on clinicaltrials.gov, but with more accessibility and ease of use.
The site was founded by Tim Burr, a tech entrepreneur and biotech investor. After much time toiling on clinicaltrials.gov, he knew there was a problem that needed solving. Tim says, ''we wanted to create a platform to ease the tedium and information overload users face when analyzing and sorting through clinical trial data. Given its importance, clinical trial data needs to be ultra-accessible for anyone that needs it.''
What to expect:
People who need to access clinical trial information have been asking for a tool to simplify the monitoring and analyzation of clinical trial data, and Primary Endpoints wants to be the answer. With Primary Endpoints:
· Trial tracking is made easy with customized visual timelines.
· Trial outcomes are predicted by biotech experts.
· Customized notifications of trial updates ensure you are among the first to know.
· Communication with biotech experts and gurus is made easy.
· Join discussion boards and engage with clinical and investing experts.
Be among the first.
Don't miss the opportunity to be among the first to discover this next generation platform for clinical trial data. Visit http://www.primaryendpoints.com/ to experience Primary Endpoints for yourself.
Contact:
Product Manager: Bhavana Singh
Scopic Software 12 Carly Circle Rutland MA 01543 US Phone: (855) 717-5586 (toll free)
Email: marketing@primaryendpoints.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
